Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan in Fontan-palliated Subjects (RUBATO OL)
NCT03775421Phase 3Terminated
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Apr 2019
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, open-label, single-arm trial of macitentan in congenital heart disease (CHD), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events up to 133 weeks, Number of Participants With Treatment-emergent Serious AEs up to 133 weeks and 1 more. Started Apr 2019; status: terminated.
02
Drugs
macitentan
03
Conditions
congenital heart disease (CHD)
Beyond the preview
Go deeper on NCT03775421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03775421.